secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001619856-23-000035
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Q4 net loss $27M; cash $317M; CB-010 data update planned H2 2023
------------------------------------------------------------------------

- Net loss of $27.0M in Q4 2022 and $99.4M for full year 2022, vs. $18.5M and $66.9M in 2021.
- Cash, equivalents, and marketable securities $317.0M as of Dec 31, 2022; runway into 2025.
- CB-010 ANTLER trial: all 6 pts at dose level 1 achieved complete response; 6-month CR in 3/6.
- CB-011 CaMMouflage trial recruiting at dose level 1 for r/r multiple myeloma; CB-012 IND planned H2 2023.
- R&D expenses $25.7M in Q4 2022 vs. $15.1M in Q4 2021, driven by pipeline advancement and headcount.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000035/0001619856-23-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000035/crbu-20230309.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer